Pharvaris Announces Publication Of Data From Two Randomized Phase 2 Studies, CHAPTER-1 And RAPIDe-1, Evaluating Efficacy And Safety Of Deucrictibant For Prophylaxis And On-Demand Treatment Of HAE Attacks, In The Lancet Haematology

Pharvaris has published data from two randomized Phase 2 studies, CHAPTER-1 and RAPIDe-1, in The Lancet Haematology, demonstrating the efficacy and safety of deucrictibant, an oral bradykinin B2 receptor antagonist for managing hereditary angioedema (HAE). The studies provide evidence supporting the viability of bradykinin B2 receptor antagonism in treating HAE attacks. Pharvaris focuses on addressing unmet needs in bradykinin-mediated diseases.